MULTIPLE SCLEROSIS Oral laquinimod for MS-bringing the brain into focus

Brueck, WolfgangWolfgangBrueckVollmer, Timothy L.Timothy L.Vollmer2018-11-072018-11-072013https://resolver.sub.uni-goettingen.de/purl?gro-2/28034Currently approved multiple sclerosis (MS) treatments mainly target the peripheral immune system, thereby reducing relapse rates and MRI markers of inflammation. A recent phase III trial indicates that laquinimod, a new orally active immunomodulator, has a CNS-intrinsic mode of action that is independent of effects on the peripheral immune response.MULTIPLE SCLEROSIS Oral laquinimod for MS-bringing the brain into focusjournal_article10.1038/nrneurol.2013.23424275930000329216600003